Recently, selpercatinib and prasletinib were granted approval from the Food and Drug Administration (FDA), and selpercatinib was granted approval from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the treatment of patients with advanced or metastatic RET-mutant MTC or radioactive iodine-refractory RET fusion-positive TC patients [13–15]. Here, RET is linked to medullary thyroid gland carcinoma.